Compare Stocks: DSGN, GRAL, IDYA, and VCYT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$12.24 -4.4%	$13.88	$5.28 ▼ $17.25	$766M	1.66	670,156 shs	2.55 million shs
GRAL GRAIL	$80.77 +1.0%	$74.12	$39.29 ▼ $118.84	$3.61B	3.25	700,928 shs	3.00 million shs
IDYA IDEAYA Biosciences	$38.41 -0.5%	$37.70	$25.27 ▼ $42.68	$3.37B	-0.07	641,897 shs	2.49 million shs
VCYT Veracyte	$39.79 -1.9%	$47.29	$29.45 ▼ $60.91	$3.20B	1.93	1.20 million shs	2.67 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	0.00%	-16.34%	-21.34%	-1.61%	+105.71%
GRAL GRAIL	0.00%	+5.96%	+3.59%	+26.72%	+110.78%
IDYA IDEAYA Biosciences	0.00%	+2.18%	-1.79%	+22.99%	+57.16%
VCYT Veracyte	0.00%	-2.64%	-4.79%	-25.81%	+25.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$12.24 -4.4%	$13.88	$5.28 ▼ $17.25	$766M	1.66	670,156 shs	2.55 million shs
GRAL GRAIL	$80.77 +1.0%	$74.12	$39.29 ▼ $118.84	$3.61B	3.25	700,928 shs	3.00 million shs
IDYA IDEAYA Biosciences	$38.41 -0.5%	$37.70	$25.27 ▼ $42.68	$3.37B	-0.07	641,897 shs	2.49 million shs
VCYT Veracyte	$39.79 -1.9%	$47.29	$29.45 ▼ $60.91	$3.20B	1.93	1.20 million shs	2.67 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	0.00%	-16.34%	-21.34%	-1.61%	+105.71%
GRAL GRAIL	0.00%	+5.96%	+3.59%	+26.72%	+110.78%
IDYA IDEAYA Biosciences	0.00%	+2.18%	-1.79%	+22.99%	+57.16%
VCYT Veracyte	0.00%	-2.64%	-4.79%	-25.81%	+25.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	34.80% Upside
GRAL GRAIL	2.33	Hold	$70.30	-12.96% Downside
IDYA IDEAYA Biosciences	2.80	Moderate Buy	$52.69	37.18% Upside
VCYT Veracyte	2.82	Moderate Buy	$55.78	40.18% Upside

Current Analyst Ratings Breakdown

Latest DSGN, GRAL, IDYA, and VCYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/15/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/9/2026	IDYA IDEAYA Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$54.00 ➝ $57.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/1/2026	IDYA IDEAYA Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
GRAL GRAIL	$147.17M	24.52	N/A	N/A	$66.13 per share	1.22
IDYA IDEAYA Biosciences	$218.71M	15.43	N/A	N/A	$11.67 per share	3.29
VCYT Veracyte	$517.15M	6.19	$1.49 per share	26.72	$16.57 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	28.22	25.84	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest DSGN, GRAL, IDYA, and VCYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	18.86	18.86
GRAL GRAIL	N/A	10.95	10.95
IDYA IDEAYA Biosciences	N/A	10.45	10.45
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
GRAL GRAIL	N/A
IDYA IDEAYA Biosciences	98.29%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	17.10%
GRAL GRAIL	1.83%
IDYA IDEAYA Biosciences	4.70%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
IDYA IDEAYA Biosciences	145	87.86 million	83.73 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable

DSGN, GRAL, IDYA, and VCYT Headlines

Recent News About These Companies

Bank of America Corp DE Invests $64.74 Million in Veracyte, Inc. $VCYT

September 20 at 3:20 AM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

September 19 at 5:08 PM | theglobeandmail.com

Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT

September 19 at 3:43 AM | marketbeat.com

Jens Holstein Sells 5,000 Shares of Veracyte (NASDAQ:VCYT) Stock

September 18 at 5:57 AM | americanbankingnews.com

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT

September 17 at 3:27 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares

September 16, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) & Veracyte (NASDAQ:VCYT) Financial Comparison

September 16, 2026 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of "Moderate Buy" by Analysts

September 16, 2026 | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

September 15, 2026 | marketscreener.comM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Veracyte, Inc.: Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 15, 2026 | finanznachrichten.de

Veracyte Buys Convergent Genomics

September 14, 2026 | finance.yahoo.com

Veracyte Acquires Convergent Genomics For $150 Mln In Cash

September 14, 2026 | rttnews.com

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 14, 2026 | globenewswire.com

Why (VCYT) Price Action Is Critical for Tactical Trading

September 13, 2026 | news.stocktradersdaily.comN

Veracyte (NASDAQ:VCYT) Upgraded at UBS Group

September 12, 2026 | marketbeat.com

Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors

September 9, 2026 | gurufocus.com

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

September 9, 2026 | zacks.com

Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares

September 5, 2026 | insidertrades.com

Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock

September 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, GRAL, IDYA, and VCYT Company Descriptions

Design Therapeutics NASDAQ:DSGN

$12.24 -0.57 (-4.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.26 +0.02 (+0.12%)

As of 09/18/2026 07:30 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

GRAIL NASDAQ:GRAL

$80.77 +0.82 (+1.03%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$80.96 +0.19 (+0.23%)

As of 09/18/2026 07:31 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

IDEAYA Biosciences NASDAQ:IDYA

$38.41 -0.20 (-0.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$37.86 -0.55 (-1.43%)

As of 09/18/2026 07:30 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Veracyte NASDAQ:VCYT

$39.79 -0.78 (-1.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$39.52 -0.27 (-0.67%)

As of 09/18/2026 07:59 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, GRAL, IDYA, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, GRAL, IDYA, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, GRAL, IDYA, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, GRAL, IDYA, and VCYT Company Descriptions

Design Therapeutics NASDAQ:DSGN

GRAIL NASDAQ:GRAL

IDEAYA Biosciences NASDAQ:IDYA

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, GRAL, IDYA, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, GRAL, IDYA, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, GRAL, IDYA, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, GRAL, IDYA, and VCYT Company Descriptions

Design Therapeutics NASDAQ:DSGN

GRAIL NASDAQ:GRAL

IDEAYA Biosciences NASDAQ:IDYA

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools